Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

作者: Hara Levy , Leslie A. Kalish , Carolyn L. Cannon , K. Christopher García , Craig Gerard

DOI: 10.1002/PPUL.20794

关键词:

摘要: Rationale Chronic mucoid Pseudomonas aeruginosa within the airway in cystic fibrosis (CF) patients can determine prognosis. Understanding risk factors of P. acquisition may change how we deliver care. This study aims to evaluate whether presence reported predict disease severity including gender, CFTR genotype, bacterial organisms cultures, and serum levels vitamins A E, albumin, C-reactive protein, alpha 1-antitrypsin, immunoglobulins increased acquisition. Methods Primary endpoint was age at first transition from negative positive culture for aeruginosa. Cox proportional hazards regression with time-dependent covariates examined development infection its association longitudinally measured biomarkers, pulmonary function, results other organisms. Results Median ages CF diagnosis were 0.55 5.7 years, respectively. Median number cultures/patient 17. Of 323 subjects, 150 developed during a median 8.1 years' follow-up. In multivariate analysis, gender (relative hazard [RH] male vs. female, P = 0.001), DF508 alleles (RH 1.66 1 or 2 0, P = 0.04), FEV1 % 1.16 10% decrease, P = 0.008), most recent Staphylococcus aureus status 0.24 negative, P < 0.0001) remained statistically significant. Conclusion Female alleles, decreased lung lack S. on sputum are important early detection Pediatr Pulmonol. 2008; 43:463–471. © 2008 Wiley-Liss, Inc.

参考文章(34)
Catharine J. Holberg, Michael D. Lebowitz, Ronald J. Knudson, Benjamin Burrows, Changes in the normal maximal expiratory flow-volume curve with growth and aging. The American review of respiratory disease. ,vol. 127, pp. 725- 734 ,(2015) , 10.1164/ARRD.1983.127.6.725
Michael R. Kosorok, Muhammad Jalaluddin, Philip M. Farrell, Guanghong Shen, Christopher E. Colby, Anita Laxova, Michael J. Rock, Mark Splaingard, Comprehensive analysis of risk factors for acquisition ofPseudomonas aeruginosa in young children with cystic fibrosis Pediatric Pulmonology. ,vol. 26, pp. 81- 88 ,(1998) , 10.1002/(SICI)1099-0496(199808)26:2<81::AID-PPUL2>3.0.CO;2-K
S. S. Wang, S. C. FitzSimmons, L. A. O'Leary, M. J. Rock, M. L. Gwinn, M. J. Khoury, Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: A registry-based longitudinal study. Pediatrics. ,vol. 107, pp. 274- 279 ,(2001) , 10.1542/PEDS.107.2.274
S ABMAN, J OGLE, R HARBECK, N BUTLERSIMON, K HAMMOND, F ACCURSO, Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. The Journal of Pediatrics. ,vol. 119, pp. 211- 217 ,(1991) , 10.1016/S0022-3476(05)80729-2
Judith H. Maselli, Marci K. Sontag, Jill M. Norris, Todd MacKenzie, Jeff S. Wagener, Frank J. Accurso, Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening. Pediatric Pulmonology. ,vol. 35, pp. 257- 262 ,(2003) , 10.1002/PPUL.10230
M. Fayon, CF-Emerging therapies: Modulation inflammation Paediatric Respiratory Reviews. ,vol. 7, pp. S170- S174 ,(2006) , 10.1016/J.PRRV.2006.04.212
Richard L. Henry, Craig M. Mellis, Lea Petrovic, Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatric Pulmonology. ,vol. 12, pp. 158- 161 ,(1992) , 10.1002/PPUL.1950120306
H.K. Johansen, M. Nir, C. Koch, M. Schwartz, N. Høiby, Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutation The Lancet. ,vol. 337, pp. 631- 634 ,(1991) , 10.1016/0140-6736(91)92449-C